Biomarkers may help predict outcomes in gastric cancer patients who abuse alcohol

January 10, 2018, Elsevier
Immunohistochemical staining of transcription factor IIB-related factor 1 (BRF1) in gastric cancer (GC). A and B: High BRF1 expression in GC tissue. C: Positive BRF1 expression in GC para-tumor tissue. D and E: Low BRF1 expression in GC tissue. F: Negative BRF1 expression in GC para-tumor tissue. Original magnification: x100 (A and D); x400 (B, C, E, and F). Credit: The American Journal of Pathology

Alcohol consumption has been identified as a modifiable risk factor for cancers such as gastric cancer. A new report in the The American Journal of Pathology sheds light on how specific proteins interact with alcohol, and how that interplay impacts survival and response to platinum-based adjuvant chemotherapy in patients with gastric cancer who may or may not still be drinking. It is the first time that a correlation between a key microRNA-processing modulator, transcription factor IIB-related factor 1 (BRF1), and prognosis of gastric cancer patients has been demonstrated. Investigators also determined that breast cancer susceptibility gene BRCA1/2, and myeloperoxidase (MPO) are more frequent in gastric cancer patients who engage in hazardous or harmful alcohol consumption.

"Alcohol consumption is a known risk factor for gastric cancer, which carries high morbidity and mortality in China. We found that DNA repair-related markers—BRF1, BRCA1/2, and MPO—have good prognostic value in gastric cancer with or without harmful consumption habits. Moreover, these proteins are also associated with how effective platinum-based adjuvant chemotherapy will be for gastric cancer patients," explained Hua Wang, MD, PhD, and co-senior author Kangsheng Gu, MD, PhD, both of the Department of Oncology at First Affiliated Hospital of Anhui Medical University, Hefei, Anhui (China).

Researchers analyzed tumor tissue from 77 patients who had undergone surgery for primary gastric adenocarcinoma and 69 tissue samples taken from outside the tumor area. Among them, 66 patients received radical surgery and 57 patients received platinum-based adjuvant chemotherapy. All 77 patients were followed for an average of 18 months, during which time 94% (62/66) experienced disease recurrence. Patients remained free of disease for an average of 14 months (disease free survival, DFS) whereas the median overall survival (OS) was 20 months.

BRF1, BRCA1/2, and MPO were also helpful in predicting which patients would benefit more from platinum-based adjuvant chemotherapy. For example, DFS was extended two-fold or more in patients who underwent chemotherapy and showed negative or low BRCA1/2 expression. For those with negative or low BRCA1, the average disease-free interval was 18 months compared to nine months in the high-expression group. Patients with negative MPO also had a better outcome trend, although it was not statistically significant.

Importantly, investigators found that alcohol continued to have a detrimental effect in patients. High BRF1 expression and MPO-positive inflammatory cell infiltration were more frequent in gastric cancer patients with hazardous or harmful alcohol consumption habits. Abnormal changes in BRCA1 in tissues outside the tumors were more frequent in alcohol abusers. In previous studies, these investigators found similar correlations between BRF1 and alcohol consumption in breast and liver patients.

Understanding the mechanisms of how these proteins interact with alcohol and contribute to carcinogenesis is still being investigated. It is thought that RNA Pol III transcribes genes play a crucial role in alcohol-mediated tumorigenesis. BRF1 regulates RNA Pol III gene transcription, and its overexpression acts though BRCA1 to alleviate inhibition of RNA Pol III transcription. Measurement of MPO is interpreted as a measure of the gastric inflammation and oxidative damage induced by alcohol. BRCA1/2 and MPO also play key roles in DNA damage repair.

"Until now, there have been no good markers to indicate in tissue," noted Dr. Wang. "Future larger clinical trials are planned to explore the prognostic utility of these biomarkers in gastric and other cancers in patients who consume hazardous quantities of alcohol."

Explore further: Increase in risk of certain gastric cancer from heavy drinking

More information: Yiyin Zhang et al, Prognostic Value of the Expression of DNA Repair–Related Biomarkers Mediated by Alcohol in Gastric Cancer Patients, The American Journal of Pathology (2018). DOI: 10.1016/j.ajpath.2017.10.010

Related Stories

Increase in risk of certain gastric cancer from heavy drinking

May 18, 2011
The results from a very well-done meta-analysis support other data generated on the risk of alcohol consumption and gastric cancer – that is – that the risk may be real for heavy alcohol consumption but not for ...

Early drivers of gastric cancer

August 9, 2017
Gastric cancer – a leading cause of cancer-related deaths worldwide – is commonly diagnosed at a late stage when most patients have a poor prognosis.

Mutational signatures may ID pts with Br Ca most likely to benefit from platinum-based chemo

December 19, 2017
The presence in advanced breast cancer of mutational signatures characteristic of homologous recombination deficiency (HRD) was associated with improved clinical outcomes to treatment with platinum-based chemotherapy.

Treatment based On BRCA1 level does not increase survival of stage II/III NSCLC N+ resected patients

October 17, 2017
New research shows that treating stage II and III non-small cell lung cancer (NSCLC) N+ resected patients with customized chemotherapy (CT) treatment based on their specific BRCA1 expression levels, as opposed to providing ...

Even one drink a day can increase risk of cancer, study finds

November 13, 2017
Do you enjoy the occasional cocktail? Beware, because even moderate consumption of alcohol can increase your risk of cancer, according to a new report.

Differences in subtypes of gastric cancer may determine prognosis and response to treatment

July 26, 2017
Molecular classification of the four distinct subtypes of gastric cancer could potentially shape tailored treatment options by helping to predict survival outcomes and patients' response to chemotherapy.

Recommended for you

An artificial mole as an early warning system

April 18, 2018
Alongside cardiovascular disease, cancer has become the top cause of death in industrialised countries. Many of those affected are diagnosed only after the tumour has developed extensively. This often reduces the chance of ...

Delivering cancer treatment on a nanodisc helps eliminate tumors

April 18, 2018
In the wrestling match with cancer, chemoimmunotherapy is the new strong arm, and it is building muscle with a nanodisc disguised as "good cholesterol."

Spouses can boost early detection for melanoma patients

April 18, 2018
There's an extra bonus to marriage for melanoma patients: They tend to be diagnosed in earlier more treatable stages than patients who are unmarried, widowed or divorced, a new study says.

Scientists discover sweet spot of activity in immune system key to fighting cancer

April 18, 2018
Scientists at the University of Southampton have shown how stimulating a specific location on the surface of immune cells can be targeted with antibodies to help in their fight against cancer.

Potential lines of attack against prostate cancer

April 17, 2018
Researchers from The University of East Anglia (UEA) have contributed to the world's largest study into genes that drive prostate cancer – identifying 80 molecular weaknesses that could be targeted by drugs to treat the ...

Scientists find some human cancers to be 'evolutionary accidents'

April 17, 2018
New research, published in Biological Reviews and conducted by researchers from the University of Liverpool and Escola Superior de Ciências da Saúde (Brasília, Brazil) has found some type of cancers unique to humans may ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.